Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis

Neurotrophic keratitis/keratopathy (NK), a rare degenerative corneal disease, lacks effective pharmacologic therapies.1 Because NK pathology involves trigeminal nerve damage and loss of corneal innervation, nerve growth factor (NGF) is surmised to promote healing of NK.2 Preliminary studies with murine NGF demonstrated efficacy for treating corneal neurotrophic ulcers;3 however, the complex tertiary structure of NGF has complicated the production of recombinant human NGF (rhNGF) suitable for clinical development.

Source: Ophthalmology - April 10, 2018 Category: Opthalmology Authors: Stefano Bonini, Alessandro Lambiase, Paolo Rama, Isabella Filatori, Marcello Allegretti, Wendy Chao, Flavio Mantelli, REPARO Study Group Tags: Reports Source Type: research